3Choi HK, Merkel PA, Walker AM, et al. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum, 2000, 43: 405-413.
4Fujieda M, Hattori M, Kurayama H, et al. Clinical features and outcomes in children with antineutrophil cytoplasmic autoantibody-positive glomerulonephritis associated with propylthiouracil treatment. J Am Soc Nephrol, 2002, 13 : 437-445.
5Claassen E. Immunocyto chemical antigen-specific detection of antibodies. In: Lefkovits I, ed. Immunology Methods Mannal. New York: Acad Press, 1997. 1051-1052.
6Short AK, Lockwood CM. Studies of epitope restriction on myeloperoxidase (MPO), an important antigen in systemic vasculitis. Clin Exp Immunol, 1997, 110: 270-276.
7Falk RJ, Terrell RS, Charles LA, et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A , 1990, 87: 4115-4119.
8Arimura Y, Minoshima S, Kamiya Y, et al. Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. Clin Nephrol, 1993, 40: 256-264.
9Jayne DR, Gaskin G, Pusey CD, et al. ANCA and predicting relapse in systemic vasculitis. QJM, 1995, 88: 127-133.
10Cohen P, Guillevin L, Baril L, et al. Persistence of antineutropil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients. Clin Exp Rheumatol, 1995,13: 193-198.
